Captopril - Revision history

Zeki: /* Drug Management */

2024-09-23T01:04:21Z

Drug Management

← Older revision		Revision as of 21:04, 22 September 2024
Line 137:		Line 137:

	Need to reduce the dose.		Need to reduce the dose.
	*If eGFR >40 mL/minute/1.73 m2		*If eGFR >40 mL/minute/1.73 m<sup>2</sup>
	**Max. initial dose 50 mg		**Max. initial dose 50 mg
	*If eGFR 20 – 40 mL/minute/1.73 m2		*If eGFR 20 – 40 mL/minute/1.73 m<sup>2</sup>
	**Max. initial dose 25 mg (do not exceed 100 mg daily)		**Max. initial dose 25 mg (do not exceed 100 mg daily)
	*If eGFR 10 – 20 mL/minute/1.73 m2		*If eGFR 10 – 20 mL/minute/1.73 m<sup>2</sup>
	**Max. initial dose 12.5 mg (do not exceed 75 mg daily)		**Max. initial dose 12.5 mg (do not exceed 75 mg daily)
	*If eGFR <10 mL/minute/1.73 m2		*If eGFR <10 mL/minute/1.73 m<sup>2</sup>
	**Max. initial dose 6.25 mg (do not exceed 37.5 mg daily)		**Max. initial dose 6.25 mg (do not exceed 37.5 mg daily)

Zeki: /* FAQs */

2024-09-23T01:03:15Z

FAQs

← Older revision		Revision as of 21:03, 22 September 2024
Line 162:		Line 162:
	*Use with care in patients with severe or symptomatic aortic stenosis (risk of hypotension)		*Use with care in patients with severe or symptomatic aortic stenosis (risk of hypotension)

	==~~FAQs~~==		==FAQ==
	'''How should I take the tablet?		'''How should I take the tablet?

Zeki: /* Side Effects */

2024-09-23T01:02:35Z

Side Effects

← Older revision		Revision as of 21:02, 22 September 2024
Line 59:		Line 59:
	!Adverse reactions		!Adverse reactions
	\|-		\|-
	\| rowspan="12" \|'''Common ~~(≥1/100 to <1/10)~~		\| rowspan="12" \|'''Common Side Effect
	\| Sleep disorders		\| Sleep disorders
	\|-		\|-
Line 84:		Line 84:
	\| Dyspepsia		\| Dyspepsia
	\|-		\|-
	\| rowspan="7" \| '''Uncommon ~~(≥1/1,000 to <1/100)~~		\| rowspan="13" \| '''Uncommon Side Effect
	\| Tachycardia		\| Tachycardia
	\|-		\|-
Line 99:		Line 99:
	\| Pallor		\| Pallor
	\|-		\|-
	~~\| rowspan="2" \|'''Rare (≥1/10,000 to <1/1,000)~~
	\| Stomatitis		\| Stomatitis
	\|-		\|-
	\| Small bowel angioedema		\| Small bowel angioedema
	\|-		\|-
	~~\| rowspan="4" \|'''Very rare (<1/10,000)~~
	\| Confusion		\| Confusion
	\|-		\|-

Zeki at 07:04, 9 September 2024

2024-09-09T07:04:59Z

← Older revision		Revision as of 03:04, 9 September 2024
Line 5:		Line 5:
	'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]		'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]

	'''Captopril (CAPOTEN)''' ~~(中文：~~[[卡托普利]])		'''Captopril (CAPOTEN)'''（中文：[[卡托普利]]）
	==Pronunciation==		==Pronunciation==
	===Captopril 12.5mg===		===Captopril 12.5mg===

Zeki at 02:47, 5 September 2024

2024-09-05T02:47:57Z

← Older revision		Revision as of 22:47, 4 September 2024
Line 5:		Line 5:
	'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]		'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]

	'''Captopril''' (中文：[[卡托普利]])		'''Captopril (CAPOTEN)''' (中文：[[卡托普利]])
	==Pronunciation==		==Pronunciation==
	===Captopril 12.5mg===		===Captopril 12.5mg===

Zeki at 01:43, 5 September 2024

2024-09-05T01:43:50Z

← Older revision		Revision as of 21:43, 4 September 2024
Line 5:		Line 5:
	'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]		'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]

	'''Captopril''' (~~中文:~~ [[卡托普利]])		'''Captopril''' (中文：[[卡托普利]])
	==Pronunciation==		==Pronunciation==
	===Captopril 12.5mg===		===Captopril 12.5mg===

Zeki at 01:36, 5 September 2024

2024-09-05T01:36:15Z

← Older revision		Revision as of 21:36, 4 September 2024
Line 1:		Line 1:
	[[Category: Drugs]][[Category: ACE inhibitors]]		[[Category: Drugs]][[Category: ACE inhibitors]]

			[[:Category: Cardiovascular Drug \| '''Cardiovascular Drug''']]

			'''Drug class: [[:Category: ACE inhibitors \| Angiotensin Converting Enzyme Inhibitors, ACEI]]

	'''Captopril''' (中文: [[卡托普利]])		'''Captopril''' (中文: [[卡托普利]])

Helen: /* Drug Management */

2024-06-20T08:20:03Z

Drug Management

← Older revision		Revision as of 04:20, 20 June 2024
Line 126:		Line 126:
	Should be avoided in pregnancy unless essential.		Should be avoided in pregnancy unless essential.

	'''Breast ~~Ffeeding~~		'''Breast Feeding
	*Should be avoided in the few weeks after delivery, particularly in preterm infants.		*Should be avoided in the few weeks after delivery, particularly in preterm infants.
	**Risk of profound neonatal hypotension.		**Risk of profound neonatal hypotension.

Zeki: /* Pharmacokinetics */

2024-06-14T02:25:40Z

Pharmacokinetics

← Older revision		Revision as of 22:25, 13 June 2024
Line 111:		Line 111:

	==Pharmacokinetics==		==Pharmacokinetics==
	Captopril is an orally active drug that does not require biotransformation for activity.		*Captopril is an orally active drug that does not require biotransformation for activity.
			*The average minimal absorption is approximately 75%.
	The average minimal absorption is approximately 75%.		*Peak plasma concentrations are reached within 60-90 minutes. The presence of food in the gastrointestinal tract reduces absorption by about 30 – 40%.
			*Approximately 25% to 30% of the circulating drug is bound to plasma proteins.
	Peak plasma concentrations are reached within 60-90 minutes. The presence of food in the gastrointestinal tract reduces absorption by about 30 – 40%.		*The apparent elimination half-life of unchanged captopril in blood is about 2 hours. Greater than 95% of the absorbed dose is eliminated in the urine within 24 hours. Impaired renal function could result in drug accumulation. Therefore, in patients with impaired renal function the dose should be reduced and/or dosage interval prolonged.

	Approximately 25% to 30% of the circulating drug is bound to plasma proteins.

	The apparent elimination half-life of unchanged captopril in blood is about 2 hours. Greater than 95% of the absorbed dose is eliminated in the urine within 24 hours. Impaired renal function could result in drug accumulation. Therefore, in patients with impaired renal function the dose should be reduced and/or dosage interval prolonged.

	==Drug Management==		==Drug Management==

Zeki: /* Dosages */

2024-06-14T02:02:06Z

Dosages

← Older revision		Revision as of 22:02, 13 June 2024
Line 40:		Line 40:

	*After myocardial infarction		*After myocardial infarction

	**Adult: Initially 6.25 mg daily, then increased to 12.5 mg 3 times a day for 2 days, then increased if tolerated to 25 mg 3 times a day, then increased if tolerated to 75 – 150 mg daily in 2-3 divided doses, doses to be increased gradually.		**Adult: Initially 6.25 mg daily, then increased to 12.5 mg 3 times a day for 2 days, then increased if tolerated to 25 mg 3 times a day, then increased if tolerated to 75 – 150 mg daily in 2-3 divided doses, doses to be increased gradually.
	Captopril is used prophylactically in clinically stable patients with symptomatic or asymptomatic left ventricular dysfunction to improve survival, delay the onset of symptomatic heart failure, and reduce recurrent infarction.		**Captopril is used prophylactically in clinically stable patients with symptomatic or asymptomatic left ventricular dysfunction to improve survival, delay the onset of symptomatic heart failure, and reduce recurrent infarction.

	*Diabetic nephropathy (microalbuminuria > 30 mg/day) in type 1 diabetes		*Diabetic nephropathy (microalbuminuria > 30 mg/day) in type 1 diabetes